Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
276 studies found for:    Cerebral Atrophy
Show Display Options
RSS Create an RSS feed from your search for:
Cerebral Atrophy
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed
Has Results
A Clinical Study Evaluating the Effects of Memantine on Brain Atrophy in Patients With Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: Memantine;   Drug: Placebo
2 Completed Influence of Age on Amyloid Load in Alzheimer's Disease and in Atypical Focal Cortical Alzheimer's Disease
Conditions: Alzheimer's Disease;   Posterior Cortical Atrophy;   Logopenic Progressive Aphasia
3 Recruiting Comparison of Brain Atrophy Rates, Cognition, and Patient-Reported Outcomes in MS Patients Using Long-term Fingolimod and Glatiramer Acetate
Condition: Multiple Sclerosis
4 Recruiting Does Long-Term Natalizumab (NTZ) Therapy Normalize Brain Atrophy Rates and Quality of Life (QOL) in Relapsing Remitting Multiple Sclerosis (RRMS)?
Condition: Multiple Sclerosis
5 Completed Sunphenon in Progressive Forms of Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: Sunphenon EGCG;   Drug: Placebo
6 Completed Focal Cortical Atrophy After Myocardial Internal Capsule
Condition: Ischemic Stroke Involving Corticospinal Tract.
Intervention: Other: Additional MRI
7 Completed A Longitudinal Study of Brain Atrophy in MS Patients Over 5 Years
Condition: Multiple Sclerosis
8 Completed Evaluation of Brain Atrophy in CIS Patients on Avonex
Condition: Multiple Sclerosis
9 Recruiting Effect of Fingolimod on Neurodegeneration
Conditions: Cognition,;   Brain Volume Loss
Intervention: Drug: 0,5 mg Fingolimod
10 Recruiting Evaluating the Impact of Cerebral Ischemic And Degenerative Changes On Cognition
Condition: Cognitive Decline
11 Recruiting Structural and Functional Brain Reorganization in Neuropathic Pain. Influences of the Loss of Sensitivity and the Atrophy Cortical on Activations Due to Stimulation Allodynic
Condition: Neuropathic Pain
Interventions: Other: stimulation on painful area (area allodynic);   Other: same stimulation on non-painful area;   Radiation: MRI scan
12 Not yet recruiting Molecular and Structural Imaging in Atypical Alzheimer's Disease: A Longitudinal Study
Conditions: Atypical Alzheimer's Disease;   Logopenic Progressive Aphasia (LPA);   Posterior Cortical Atrophy (PCA)
Interventions: Drug: F-18 AV 1451;   Drug: C-11 PiB
13 Active, not recruiting Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
Conditions: Autoimmune Diseases of the Nervous System;   Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis;   Disease Progression;   Brain Atrophy
Interventions: Biological: Tcelna;   Biological: Placebo
14 Recruiting Aerobic Exercise and Brain Health in Multiple Sclerosis
Conditions: Multiple Sclerosis;   Brain Atrophy;   Cognitive Impairment
Intervention: Other: Aerobic exercise
15 Active, not recruiting Tau Imaging in Young Onset Dementia
Conditions: Alzheimer's Disease, Early Onset;   Logopenic Progressive Aphasia;   Posterior Cortical Atrophy (PCA)
Intervention: Drug: [18F]-T807 imaging tracer
16 Completed Investigation of Simvastatin in Secondary Progressive Multiple Sclerosis
Condition: Secondary Progressive Multiple Sclerosis
Interventions: Drug: Simvastatin;   Drug: Placebo
17 Completed Gait and Alzheimer Interaction Tracking (GAIT) Study
Conditions: Gait Apraxia;   Alzheimer Disease;   Impaired Cognition;   Cerebral Atrophy
18 Completed Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
Condition: Multiple Sclerosis
Interventions: Drug: Fingolimod;   Drug: Interferon beta 1b
19 Withdrawn Safety and Brain Protection Effects of the Green Tea Extract Theaphenon 95% (95% Pure EGCG) in Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: 95% Pure ECGC capsules 200mg;   Drug: Placebo Comparator:
20 Unknown  A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: Avonex and Topamax

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years